




The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 27% points. The greatest weakness of Ernexa Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 105%, being 124% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	3,133
Cost of Goods Sold	0
Intangible Assets	2,044
Liabilities, Current	3,113
Liabilities, Non-Current	320
Other Assets	563
Other Compr. Net Income	0
Other Expenses	-45
Other Liabilities	0
Other Net Income	-4,810
Other Revenues	0
Property and Equipment	94
Research and Development	4,156
Selling, General and Administrative Expense	5,163

Output Variable	Value in 1000 USD
Assets	5,834
Liabilities	3,433
Expenses	9,274
Revenues	0
Stockholders Equity	2,401
Net Income	-14,084
Comprehensive Net Income	-14,084
BaseVar	11,676
ECR before LimitedLiability	-191%
Economic Capital Ratio	105%